​

AbbVie (ABBV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABBV Stock Forecast

AbbVie (ABBV) stock forecast, based on 37 Wall Street analysts, predicts a 12-month average price target of $214.80, with a high of $226.00 and a low of $203.00. This represents a 21.49% increase from the last price of $176.80.

$155 $170 $185 $200 $215 $230 High: $226 Avg: $214.8 Low: $203 Last Closed Price: $176.8

ABBV Stock Rating

AbbVie stock's rating consensus is Buy, based on 37 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 26 Buy (70.27%), 11 Hold (29.73%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 37 0 11 26 Strong Sell Sell Hold Buy Strong Buy

ABBV Price Target Upside V Benchmarks

TypeNameUpside
StockAbbVie21.49%
SectorHealthcare Stocks 33.91%
IndustryDrug Manufacturers - General Stocks37.84%

Price Target Trends

1M3M12M
# Anlaysts-215
Avg Price Target-$217.50$203.87
Last Closing Price$176.80$176.80$176.80
Upside/Downside-23.02%15.31%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2551110--26
Mar, 2561110--27
Feb, 2561210--28
Jan, 2561310--29
Dec, 2481310--31
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 03, 2025Gary NachmanRaymond James$220.00$190.1415.70%24.43%
Feb 03, 2025Evan SeigermanBMO Capital$215.00$190.1413.07%21.61%
Nov 12, 2024Evan David SeigermanBMO Capital$208.00$201.613.17%17.65%
Oct 31, 2024Evan David SeigermanBMO Capital$228.00$201.5013.15%28.96%
Oct 31, 2024Charlie YangBank of America Securities$210.00$201.504.22%18.78%
Oct 31, 2024Geoff MeachamCitigroup$226.00$201.5012.16%27.83%
Oct 18, 2024Geoff MeachamBank of America Securities$195.00$188.573.41%10.29%
Oct 17, 2024Courtney BreenBernstein$203.00$190.466.58%14.82%
Aug 23, 2024Christopher RaymondRaymond James$209.00$197.355.90%18.21%
Jul 19, 2024Evan SeigermanBMO Capital$214.00$172.0124.41%21.04%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 11, 2025Morgan StanleyHoldHoldhold
Feb 03, 2025BMO CapitalOutperformOutperformhold
Feb 03, 2025GuggenheimBuyBuyhold
Nov 22, 2024Leerink PartnersOutperformupgrade
Nov 12, 2024BMO CapitalOutperformOutperformhold
Oct 31, 2024Morgan StanleyOverweightOverweighthold
Oct 31, 2024CitigroupBuyBuyhold
Oct 18, 2024Bank of America SecuritiesNeutralNeutralhold
Oct 17, 2024BMO CapitalOutperformOutperformhold
Oct 17, 2024BernsteinOutperformMarket Performinitialise

Financial Forecast

EPS Forecast

$0 $4 $8 $12 $16 $20 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.73$6.48$6.65$2.73$2.42----
Avg Forecast$10.48$12.68$13.76$11.13$10.94$12.19$13.70$15.05$16.61
High Forecast$10.69$12.93$14.12$11.24$11.61$12.77$18.63$18.63$16.97
Low Forecast$10.28$12.43$13.34$11.08$10.67$11.57$7.28$7.23$15.93
Surprise %-73.95%-48.90%-51.67%-75.47%-77.88%----

Revenue Forecast

$40B $47B $54B $61B $68B $75B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$45.80B$56.20B$58.05B$54.32B-----
Avg Forecast$45.64B$56.23B$58.27B$54.05B$56.04B$59.15B$63.51B$67.43B$71.61B
High Forecast$46.34B$57.10B$59.43B$54.35B$56.19B$59.78B$63.52B$67.44B$72.82B
Low Forecast$44.96B$55.40B$56.89B$53.94B$55.94B$58.25B$63.49B$67.41B$69.37B
Surprise %0.37%-0.07%-0.37%0.50%-----

Net Income Forecast

$0 $7B $14B $21B $28B $35B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.62B$11.54B$11.84B$4.86B$4.28B----
Avg Forecast$4.39B$11.26B$13.10B$4.82B$19.75B$21.58B$14.78B$19.27B$29.44B
High Forecast$5.54B$13.51B$15.72B$5.78B$20.59B$22.64B$33.03B$33.02B$30.08B
Low Forecast$3.24B$9.01B$10.48B$3.86B$18.91B$20.51B$12.90B$12.83B$28.24B
Surprise %5.19%2.52%-9.67%0.89%-78.34%----

ABBV Forecast FAQ

Is AbbVie stock a buy?

AbbVie stock has a consensus rating of Buy, based on 37 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 26 Buy, 11 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that AbbVie is a favorable investment for most analysts.

What is AbbVie's price target?

AbbVie's price target, set by 37 Wall Street analysts, averages $214.8 over the next 12 months. The price target range spans from $203 at the low end to $226 at the high end, suggesting a potential 21.49% change from the previous closing price of $176.8.

How does AbbVie stock forecast compare to its benchmarks?

AbbVie's stock forecast shows a 21.49% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the drug manufacturers - general stocks industry (37.84%).

What is the breakdown of analyst ratings for AbbVie over the past three months?

  • April 2025: 19.23% Strong Buy, 42.31% Buy, 38.46% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 22.22% Strong Buy, 40.74% Buy, 37.04% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 21.43% Strong Buy, 42.86% Buy, 35.71% Hold, 0% Sell, 0% Strong Sell.

What is AbbVie’s EPS forecast?

AbbVie's average annual EPS forecast for its fiscal year ending in December 2025 is $12.19, marking a 403.72% increase from the reported $2.42 in 2024. Estimates for the following years are $13.7 in 2026, $15.05 in 2027, and $16.61 in 2028.

What is AbbVie’s revenue forecast?

AbbVie's average annual revenue forecast for its fiscal year ending in December 2025 is $59.15B, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $63.51B, followed by $67.43B for 2027, and $71.61B for 2028.

What is AbbVie’s net income forecast?

AbbVie's net income forecast for the fiscal year ending in December 2025 stands at $21.58B, representing an 404.34% increase from the reported $4.28B in 2024. Projections indicate $14.78B in 2026, $19.27B in 2027, and $29.44B in 2028.